Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.
ETMarkets Smart Talk: From 1,200 to 10,000 | Abhishek Banerjee charts the next decade of SME listings in India
Abhishek Banerjee discusses the SME platform’s surge in listings, driven by companies seeking capital and liquidity. He anticipates significant growth, potentially reaching 10,000 listings in
May 26, 2025